[go: up one dir, main page]

KR20160013435A - Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle - Google Patents

Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle Download PDF

Info

Publication number
KR20160013435A
KR20160013435A KR1020140094816A KR20140094816A KR20160013435A KR 20160013435 A KR20160013435 A KR 20160013435A KR 1020140094816 A KR1020140094816 A KR 1020140094816A KR 20140094816 A KR20140094816 A KR 20140094816A KR 20160013435 A KR20160013435 A KR 20160013435A
Authority
KR
South Korea
Prior art keywords
extract
skin
cosmetic composition
wrinkle
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020140094816A
Other languages
Korean (ko)
Inventor
이은경
박효현
김선건
이유진
Original Assignee
재단법인 한국한방산업진흥원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 한국한방산업진흥원 filed Critical 재단법인 한국한방산업진흥원
Priority to KR1020140094816A priority Critical patent/KR20160013435A/en
Publication of KR20160013435A publication Critical patent/KR20160013435A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 등심초 추출물을 유효성분으로 포함하는 피부탄력 및 주름 개선용 화장료 조성물에 대한 것으로, 엘라스타제와 콜라게나제의 활성을 저해하는 효과가 우수하므로 피부탄력의 저하와 주름의 생성을 억제할 수 있어 피부탄력 및 주름 개선에 우수한 효과를 나타낸다.The present invention relates to a cosmetic composition for skin elasticity and wrinkle improvement comprising an extract of mustard seed extract as an active ingredient and is excellent in the effect of inhibiting the activity of elastase and collagenase, And exhibits excellent effects on skin elasticity and wrinkle improvement.

Description

등심초 추출물을 포함하는 피부탄력 및 주름 개선용 화장료 조성물{Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle}[0001] The present invention relates to a cosmetic composition for improving skin elasticity and wrinkle,

본 발명은 등심초 추출물을 포함하는 피부탄력 및 주름 개선용 화장료 조성물에 대한 것이다.The present invention relates to a cosmetic composition for skin elasticity and wrinkle improvement, which comprises an extract of mustard seed extract.

피부는 인체의 1차 방어막으로서 온도 및 습도의 변화, 자외선, 공해물질 등 외부 환경의 자극으로부터 체내 기관들을 보호해 주며, 체온조절 등의 생체 항상성 유지에 중요한 역할을 한다. 피부는 인체의 다른 장기와 마찬가지로 나이가 들어감에 따라 점차 노화가 진행되고, 노화의 결과로서 피부 탄력손실, 각질화, 주름 생성, 피부 위축 등의 현상이 나타나게 된다.Skin is the primary protective body of the human body. It protects the internal organs from changes in temperature and humidity, ultraviolet rays, pollutants and other external environment, and plays an important role in the maintenance of body homeostasis such as body temperature control. Like other organs in the human body, skin ages gradually as it gets older, resulting in skin elasticity loss, keratinization, wrinkle formation, and skin atrophy as a result of aging.

피부의 노화는 시간의 흐름에 따른 생리적 노화과정과 외재적 요인에 의한 노화과정으로 나누어진다. 이 중 외재적 요인으로 작용하는 자외선(UV, ultraviolet)은 각종 피부 트러블을 유발하여 기미, 주근깨, 피부 색소 침착 등의 노화 현상을 촉진하며, 피부암 등 여러 가지 피부 질환의 원인이 되기도 한다. 또한 자외선은 피부 탄력 섬유인 콜라겐과 엘라스틴을 분해하여 피부탄력을 떨어지게 하여 주름을 유발하고 표면을 거칠게 한다.Skin aging is divided into physiological aging process and aging process by exogenous factor according to time. Among these, ultraviolet rays (UV, ultraviolet) acting as external factors induce various skin troubles and promote aging phenomena such as stain, freckles and skin pigmentation, and cause skin diseases such as skin cancer. In addition, ultraviolet rays decompose collagen and elastin, which are skin elastic fibers, to reduce skin elasticity, causing wrinkles and roughening the surface.

피부의 탄력성은 진피조직의 콜라겐(collagen), 엘라스틴(elastin), 히알루론산(hyaluronic acid) 등에 의해 유지된다. 콜라겐은 세포 외 기질의 주요 구성성분으로서 진피의 90%를 차지하는 아교질 섬유성 단백질이며, 피부, 건(腱), 뼈 및 치아의 유기물질의 대부분을 형성하고, 피부의 기계적 견고성, 결합조직의 저항력 및 조직의 결합력을 부여하며, 세포 접착을 지탱하고, 세포분할과 분화를 유도하는 것으로 알려져 있다. 이러한 콜라겐은 노화에 의해 감소하며, 콜라겐의 감소는 피부의 주름 형성과 밀접한 연관이 있는 것으로 알려져 있다. 엘라스틴은 진피성분의 2~3%를 차지하는 탄성이 매우 풍부한 단백질로 콜라겐과 함께 그물망 구조를 형성하여 피부에 탄력성을 부여하며, 굴절성과 신축성이 강해 1.5배까지 늘어나므로 피부 파열을 방지하는 역할을 한다. 노화에 의하여 엘라스틴이 분해되면 진피조직의 그물망 구조결합이 끊어져 피부가 처지고 주름이 생기는 것으로 알려져 있다. 콜라겐과 엘라스틴은 모두 섬유아세포(fibroblast)에 의해 생성된다. The elasticity of the skin is maintained by the collagen, elastin, hyaluronic acid, etc. of the dermis tissue. Collagen is a major component of the extracellular matrix and is a collagenous fibrous protein that accounts for 90% of the dermis. It forms most of the organic matter in the skin, tendons, bones, and teeth, and the skin's mechanical rigidity, And tissue binding, and is known to support cell adhesion and induce cell division and differentiation. Such collagen is reduced by aging, and reduction of collagen is known to be closely related to wrinkling of the skin. Elastin is a highly elastic protein that occupies 2 to 3% of the dermis and forms a network structure with collagen to give elasticity to the skin. It has strong refraction and stretchability, which increases the skin's elasticity by 1.5 times. . When the elastin is broken down by aging, it is known that the binding of the network structure of the dermis tissue is broken, causing the skin to sag and wrinkle. Both collagen and elastin are produced by fibroblasts.

섬유아세포의 기능은 각종 성장인자(growth factor)에 의해 조절되지만, 케라티노사이트(keratinocyte)나 멜라노사이트(melanocyte)와 같은 피부 세포들에서 분비되는 사이토카인(cytokine)에 의해서도 조절된다. 정상적인 상태에서 케라티노사이트로부터 유리되는 TGF-β(transforming growth factor-β), TβRII(TGF-β receptor) 및 SGad3는, 진피 섬유아세포(dermal fibroblast)로부터 발현되는 프로콜라겐(procollagen), 피브릴린-1(fibrillin-1), 트로포엘라스틴(tropoelastin)의 발현양을 증가시켜 콜라겐과 엘라스틴의 생성을 증가시키며, MMPs(martrix metalloproteinases)와 엘라스타제(elastase)의 발현을 억제하여 콜라겐과 엘라스틴의 분해를 억제하는 것으로 보고되었다.The function of fibroblasts is regulated by a variety of growth factors, but is also regulated by cytokines secreted by skin cells such as keratinocytes and melanocytes. TGF-beta (transforming growth factor-beta), TGF-beta receptor and SGad3 released from keratinocytes under normal conditions can be obtained from procollagen expressed from dermal fibroblast, Increased expression of fibrillin-1 and tropoelastin increases the production of collagen and elastin and inhibits the expression of MMPs (martrix metalloproteinases) and elastase, resulting in the degradation of collagen and elastin .

자외선에 의해 케라티노사이트가 손상되면 TGF-β 외에도 TNF-α(tumor necrosis factor-α), PGE2 (prostaglandin E2), α-MSH(α-melanocyte stimulating hormone), GSF(granulocyte stimulating factor), IL-1(interleukin-1), IL-6, IL-8, IL-10 등이 유리된다. 유리된 IL-1, TNF-α 등은 섬유아세포에 작용하여 프로콜라겐 및 트로포엘라스틴의 발현을 억제하며, MMP-1(martrix metalloproteinase-1, "collagenase"), MMP-2, MMP-3, 엘라스타제(elastase) 등의 활성을 증가시켜 콜라겐과 엘라스틴의 분해를 촉진하게 된다. 또한, 자외선에 의해 섬유아세포가 직접적으로 상해를 받는 경우에도 콜라겐 및 엘라스틴 관련 유전자는 억제되고 이들의 분해에 관련되는 효소들의 발현은 촉진되어 주름이 증가하게 된다. 따라서, 진피 섬유아세포의 증식을 증가시키거나, 콜라겐의 합성 및 엘라스틴의 합성을 증가시키거나, 이들을 분해하는 효소를 억제함으로써 주름의 생성을 억제할 수 있다.In addition to TGF-β, tumor necrosis factor-α, prostaglandin E2, α-MSH, granulocyte stimulating factor (GSF), IL- 1, interleukin-1, IL-6, IL-8, and IL-10. Inhibition of procollagen and tropoelastin expression by acting on fibroblasts and release of IL-1, TNF-α and the like are inhibited by MMP-1 (martrix metalloproteinase-1, "collagenase"), MMP-2, MMP- And promotes the decomposition of collagen and elastin by increasing the activity of elastase and the like. In addition, even if the fibroblasts are directly injured by ultraviolet rays, the collagen and elastin-related genes are suppressed and the expression of the enzymes involved in degradation thereof is promoted and the wrinkles are increased. Therefore, it is possible to suppress the generation of wrinkles by increasing the proliferation of dermal fibroblasts, increasing the synthesis of collagen and the synthesis of elastin, or inhibiting the enzymes that degrade them.

최근 들어, 한약재는 미백, 노화방지, 피부개선, 항암 및 항균 등 복합 기능성을 가진 화장료의 재료로 제품의 유형과 제형에 관계없이 다양하게 이용되고 있다. In recent years, herbal medicines have been widely used regardless of the type and formulation of the product, as a cosmetic material having various functions such as whitening, anti-aging, skin improvement, anti-cancer and antibacterial.

골풀과에 속하는 다년생 초본식물인 등심초(燈心草){Juncus effusus L. var. decipiens Buchen . = juncus decipiens ( Buchen .) Nakai}는 골풀 및 동속 근연식물의 전초(全草) 또는 줄기 속심(골풀의 단단한 껍질을 제거한 연한 속)을 말하는 것으로, 호수초, 적수, 등심, 벽옥초, 수등심, 철등심, 저실초, 야석초라고도 불린다. 등심초는 한국, 일본, 중국, 북아메리카 등지에 분포하며, 우리나라에서는 전국의 물가나 습지에서 자란다. 등심초는 높이가 1.2~1.5m, 지름이 2.5mm 내외이며 10개 정도의 마디가 있는데, 각 마디에서는 뿌리가 나온다. 줄기의 표피는 엽록소를 함유한 동화조직으로 다당류 성분이 함유되어 있다. 줄기의 속심은 후막세포단으로서 섬유, 지방산, 단백질 등이 함유되어 있으며, 국수모양의 긴 원주형으로 바깥 면은 유백색이나 엷은 황백색이고, 누르면 납작하게 되고 세로의 가는 주름이 있는 생김새를 가진다. 이러한 줄기의 속심부위가 예로부터 약재로 사용되어 왔다.A perennial herbaceous plant belonging to the raspberry family, 灯心草 { Juncus effusus There is L. decipiens Buchen . = juncus decipiens ( Buchen .) Nakai refers to the whole grass or stem center of rush and relative plants. It is a lake, an enemy, a sirloin, a jasper, It is also called sirloin, pork loin, and yuzu. It is distributed in Korea, Japan, China, North America, etc. In Korea, it grows in the water and wetlands of the whole country. It has a height of 1.2 ~ 1.5m, a diameter of 2.5mm and has about 10 nodes, and each node has its roots. The epidermis of the stem is a fairytale tissue containing chlorophyll and contains a polysaccharide component. The inner part of the stem contains thick fiber, fatty acid, protein, etc., and it has a long cylindrical shape of noodle shape and outer surface is milky white or pale yellowish white. It has a pressed flat shape and a thin wrinkled shape. The central part of these stems have been used as medicines since ancient times.

등심초의 약리작용으로는 진통, 이뇨, 지혈작용이 알려져 있으며, 종래에 소변을 못 보며 소변을 볼 때 아픈 증상, 신우신염으로 생기는 부종, 가슴이 답답하고 잠을 자지 못하는 증상, 어린 아이의 야제증, 폐렴으로 인한 인후염, 후두염 등의 치료에 사용되어 왔다. The pharmacological actions of rosacea are known as analgesia, diuretic, and hemostatic action. When the urine is not seen in the past, it is known to cause pain, edema caused by pyelonephritis, symptoms of chest tightness and sleepiness, , Sore throat due to pneumonia, and laryngitis.

그러나, 등심초의 피부탄력 및 주름 개선효과에 대한 내용은 기재되거나 교시된 바 없다.However, the contents of the skin elasticity and the effect of improving the wrinkles of the sea mustard have not been described or taught.

1. 대한민국특허공개 제10-2009-0128119호1. Korean Patent Publication No. 10-2009-0128119 2. 대한민국특허공개 제10-2014-0047214호2. Korean Patent Publication No. 10-2014-0047214 3. 대한민국특허공개 제10-2014-0066844호3. Korean Patent Publication No. 10-2014-0066844

1. Blois MS. 1958. Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200.1. Blois MS. 1958. Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200. 2. Fellegrini N, Ka R, Yang M, Rice-Evans C. 1999. Screening of diatry carotenoids-rich fruit extracts for antioxidant activities applying 2,2'-azinobis(3-ethylenebenzeothiazoline-6-sulfonic acid) radical cation decolorization assay. Method Enzymol 299: 379-389.2. Ficegrini N, Ka R, Yang M, Rice-Evans C. 1999. Screening of diatryl carotenoids-rich fruit extracts for antioxidant activities applying 2,2'-azinobis (3-ethylenebenzeothiazoline-6-sulfonic acid) radical cation decolorization assay . Method Enzymol 299: 379-389. 3. Cannell RJ, Kellam SJ, Owsianka AM, Walker JM. 1988. Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Med 54: 10-14.3. Cannell RJ, Kellam SJ, Owsianka AM, Walker JM. 1988. Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Med 54: 10-14. 4. Wunsch, E., H.G. Heindrich. 1963. Zur quantitativen bestimmung der collagenase. Hoppe Seylers. Z. Physiol. Chem. 333:149-151.4. Wunsch, E., H.G. Heindrich. 1963. Zur quantitativa bestimmung der collagenase. Hoppe Seylers. Z. Physiol. Chem. 333: 149-151. 5. Claude, S., K. Manabu, M. Laura, and P. Lester. 1999. Antioxidants modulate acute solar ultraviolet radiationinduced NKκB activation in a human keratinocyte cell line, Free radical Biol. Med. 26, 174-183.5. Claude, S., K. Manabu, M. Laura, and P. Lester. 1999. Antioxidants modulate acute solar ultraviolet radiationinduced NKKB activation in a human keratinocyte cell line, Free radical Biol. Med. 26, 174-183. 6. Voegeli, R. 1996. Elastase and typtase determination on human skin surface. Cosmetic &Toiletries. 111, 51-58.6. Voegeli, R. 1996. Elastase and typing determination on human skin surface. Cosmetic & Toiletries. 111, 51-58. 7. Jung, H.S., J.H. Ha., Y.K. Kim., S.H. Oh., S.S. Kim., M.H. Jeong., H.Y. Lee. 2009. Effect of Rubus coreanus extracts on ultraviolet-A irradiated cultured human skin fibroblasts. Korean J. Medicinal Crop Sci. 17(5): 321-327.7. Jung, H. S., J.H. Ha., Y.K. Kim., S.H. Oh, S.S. Kim., M.H. Jeong., H.Y. Lee. 2009. Effect of Rubus coreanus extracts on ultraviolet-A irradiated cultured human skin fibroblasts. Korean J. Medicinal Crop Sci. 17 (5): 321-327. 8. Gilchrest BA. 1989. Skin aging and photoaging. Journal of the american academy of dermatology. 21:610-613.8. Gilchrest BA. 1989. Skin aging and photoaging. Journal of the american academy of dermatology. 21: 610-613. 9. Aroca, P., et al. 1993. Melanin biosynthesis patterns of following hormonal stimulation. J. Biol Chem 268, 25650-25655.9. Aroca, P., et al. 1993. Melanin biosynthesis patterns of following hormonal stimulation. J. Biol Chem 268, 25650-25655. 10. Chin, J. E., et al. 2005. Effects of Houttuynia cordata extracts on tyrosinse gene expression. J. Korean Soc Food Sci Nutr 34, 1284-1288.10. Chin, J. E., et al. 2005. Effects of Houttuynia cordata extracts on tyrosinase gene expression. J. Korean Soc Food Sci Nutr 34, 1284-1288. 11. Oikarinen A, Karvonen J, Uitto J, Hannuksela M., Connective tissue alterations in skin exposed to natural and therapeutic UV-radiation. Photodermatol. 2(1), pp.15-26, Review, 1985.11. Oikarinen A, Karvonen J, Uitto J, Hannuksela M., Connective tissue alterations in skin exposed to natural and therapeutic UV-radiation. Photodermatol. 2 (1), pp. 15-26, Review, 1985. 12. Hirobe T., Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell Res. 18(1), pp2-12. Review, 2005.12. Hirobe T., Role of keratinocyte-derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes. Pigment Cell Res. 18 (1), pp2-12. Review, 2005. 13. McKay IA, Leigh IM., Epidermal cytokines and their roles in cutaneous wound healing. Br J Dermatol. 124(6), pp.513-8, Review, 1991.13. McKay IA, Leigh IM., Epidermal cytokines and their roles in cutaneous wound healing. Br J Dermatol. 124 (6), pp.513-8, Review, 1991. 14. Kim HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH., Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. J Lipid Res. 47(5),pp.921-30, 2006.14. Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo. Kim, HH, Cho S, Lee S, Kim KH, Cho KH, Eun HC, Chung JH. J Lipid Res. 47 (5), pp.921-30, 2006. 15. Medina A, Ghaffari A, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction. Mol Cell Biochem. 305(1-2), pp.255-64, Review, 2007.15. Medina A, Ghaffarie, Kilani RT, Ghahary A., The role of stratifin in fibroblast-keratinocyte interaction. Mol Cell Biochem. 305 (1-2), pp. 255-64, Review, 2007. 16. Wang XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc. 11(1), pp.112-7, Review, 2006.16. Wang XJ, Han G, Owens P, Siddiqui Y, Li AG., Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc. 11 (1), pp. 112-7, Review, 2006. 17. Traidi-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol. 140(4), pp.315-20, 2006.17. Traidi-Hoffmann C, MI, Ring J, Behrendt H., Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol. 140 (4), pp.315-20, 2006.

이에 본 발명자들은 등심초 추출물이 피부의 탄력을 감소시키고 주름의 생성을 촉진하는 엘라스타제와 콜라게나제를 저해하는 활성이 우수한 것을 확인하여 본 발명을 완성하였다.Accordingly, the inventors of the present invention have completed the present invention by confirming that the extract of Rumex root is superior in the activity of inhibiting elastase and collagenase which reduce the elasticity of skin and promote the generation of wrinkles.

상기 목적을 달성하기 위하여, 본 발명은 등심초 추출물을 유효성분으로 포함하는 피부탄력 및 주름 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for skin elasticity and wrinkle improvement, which comprises an extract of Seaweed extract as an active ingredient.

상기 등심초 추출물은 물, C1 내지 C4의 저급 알콜 및 이들의 혼합용매로부터 선택된 용매로 추출된 것이 바람직하다.It is preferable that the rumen extract is extracted with a solvent selected from water, C 1 to C 4 lower alcohols and mixed solvents thereof.

또한 상기 조성물은 상기 등심초 추출물을 화장료 조성물 총 중량에 대하여 0.1~50중량% 포함하는 것이 바람직하다.In addition, it is preferable that the composition contains 0.1 to 50% by weight of the above-mentioned Seaweed extract based on the total weight of the cosmetic composition.

본 발명의 등심초 추출물은, 피부의 탄력성을 유지하는 성분인 엘라스틴과 콜라겐을 분해하여 피부의 탄력을 저하시키고 주름을 생성하는 엘라스타제와 콜라게나제의 활성을 저해하는 효과가 우수하다. 따라서 노화에 의해 발생하는 피부탄력의 저하와 주름의 생성을 억제할 수 있어 피부탄력 및 주름 개선을 위한 화장료 조성물로 유용하게 이용될 수 있다.The water lanceolate extract of the present invention is excellent in the effect of inhibiting the activity of elastase and collagenase, which decompose elastin and collagen, which are components that maintain elasticity of skin, to reduce elasticity of skin and produce wrinkles. Accordingly, it is possible to suppress the reduction of skin elasticity and the generation of wrinkles caused by aging, and thus it can be effectively used as a cosmetic composition for improving skin elasticity and wrinkles.

도 1은 등심초 추출물의 DPPH 라디칼 소거활성을 나타낸 그래프이다.
도 2는 등심초 추출물의 ABTS 라디칼 소거활성을 나타낸 그래프이다.
도 3은 등심초 추출물의 엘라스타제 저해 활성을 나타낸 그래프이다.
도 4는 등심초 추출물의 콜라게나제 저해 활성을 나타낸 그래프이다.
FIG. 1 is a graph showing the DPPH radical scavenging activity of the Rumex root extract. FIG.
FIG. 2 is a graph showing the ABTS radical scavenging activity of the water rumen extract.
Fig. 3 is a graph showing the elastase inhibitory activity of the raspberry extract.
Fig. 4 is a graph showing the collagenase inhibitory activity of the raspberry extract.

이하 본 발명을 상세하게 설명한다.
Hereinafter, the present invention will be described in detail.

1. One. 등심초rush 추출물의 제조 Preparation of extract

원재료인 건조상태의 등심초에 추출용매를 원재료 중량의 약 1~5배, 바람직하게는 2~4배를 가하여, 5~100℃, 바람직하게는 20~90℃, 보다 바람직하게는 실온~80℃에서 10~30시간, 바람직하게는 약 18~25시간 동안 추출한 후 여과하고 감압농축하여 등심초 추출물을 얻는다. The extraction solvent is added in an amount of about 1 to 5 times, preferably 2 to 4 times the weight of the raw material to the raw beef which is a raw material in a dry state at a temperature of 5 to 100 캜, preferably 20 to 90 캜, more preferably room temperature to 80 캜 For 10 to 30 hours, preferably about 18 to 25 hours, followed by filtration and concentration under reduced pressure to obtain an extract of Seabream extract.

상기 추출용매로는 물, C1 내지 C4의 저급 알콜 및 이들의 혼합용매로부터 선택된 용매를 사용하며, 물과 에탄올의 혼합용매를 사용하는 것이 보다 바람직하다. 추출방법으로는 냉침추출, 열수추출, 초음파추출, 환류냉각추출, 가열추출 등 당업계에서 통상적으로 사용하는 방법을 사용할 수 있으며, 냉침추출하는 것이 보다 바람직하다.
As the extraction solvent, a solvent selected from water, C 1 to C 4 lower alcohols and mixed solvents thereof is used, and a mixed solvent of water and ethanol is more preferably used. Examples of the extraction method include a method commonly used in the art such as cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction and heat extraction, and it is more preferable to perform cold extraction.

2. 피부탄력 및 주름 개선용 2. For skin elasticity and wrinkle improvement 화장료Cosmetics 조성물의 제조 Preparation of composition

본 발명의 피부탄력 및 주름 개선용 화장료 조성물은 상기 등심초 추출물을 유효성분으로 포함한다. The cosmetic composition for improving skin elasticity and wrinkles of the present invention contains the above sea mustard extract as an active ingredient.

상기 등심초 추출물은 화장료 조성물 총 중량에 대하여 0.1~50중량% 포함되는 것이 바람직하다.It is preferable that the watercress root extract is contained in an amount of 0.1 to 50% by weight based on the total weight of the cosmetic composition.

본 발명의 화장용 조성물은 당업계에서 통상적으로 제조되는 다양한 제형으로 제조될 수 있으며, 제형의 예로는 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등이 있으나 이에 한정되는 것은 아니다. 보다 상세하게는, 화장수, 로션, 수분크림, 영양크림, 마사지크림, 아이크림, 핸드크림, 에센스, 팩, 샴푸, 린스, 비누, 클렌징로션, 클렌징크림, 클렌징폼, 클렌징워터, 바디로션, 바디클렌저, 스프레이, 파우더 등의 형태로 제조될 수 있다. The cosmetic composition of the present invention can be prepared in various formulations conventionally produced in the art and examples of the formulations include solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oils, powder foundations, emulsion foundations, wax foundations and sprays, but are not limited thereto. More specifically, the present invention relates to a cosmetic lotion, a lotion, a moisture cream, a nutritional cream, a massage cream, an eye cream, a hand cream, an essence, a pack, a shampoo, a rinse, a soap, a cleansing lotion, a cleansing cream, a cleansing foam, Cleansers, sprays, powders, and the like.

상기 화장료 조성물은 상기 추출물 이외에 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및 담체를 포함할 수 있다. The cosmetic composition may contain, in addition to the above extracts, conventional auxiliaries and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances.

본 발명의 제형이 페이스트, 크림 또는 젤인 경우에는 담체 성분으로 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등을 사용할 수 있다.When the formulation of the present invention is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tracer, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide can be used as a carrier component have.

본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 하이드록사이드, 칼슘 실리케이트 또는 폴라아미드 파우더를 사용할 수 있고, 스프레이인 경우에는 추가적으로 클로로플루오로하이드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or a polyamide powder can be used as a carrier component. In the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Or propellants such as dimethyl ether.

본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로 용매, 용해화제 또는 유탁화제가 사용되고, 그 예로는 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol, glycerol aliphatic esters, polyethylene glycols or sorbitan fatty acid esters.

본 발명의 제형이 현탁액인 경우에는 담체 성분으로 물, 에탄올 및 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁화제, 미소 결정성 셀룰로오스, 알루미늄 메타하이드록사이드, 벤토나이트, 아가, 트라칸트 등이 사용될 수 있다.When the formulation of the present invention is a suspension, the carrier component may include water, a liquid diluent such as ethanol and propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar, tracant and the like may be used.

본 발명의 제형이 계면활성제-함유 클렌징인 경우에는 담체 성분으로 지방족 알콜 설페이트, 지방족 알콜 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알콜, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체, 에톡실화 글리세롤 지방산 에스테르 등이 사용될 수 있다.
When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glycerol fatty acid esters, and the like.

이하 실시예 및 실험예를 통하여 본 발명을 보다 상세하게 설명한다. 하기 실시예 및 실험예는 본 발명을 예시하는 것으로 본 발명의 범위가 이에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. The following Examples and Experimental Examples illustrate the present invention, and the scope of the present invention is not limited thereto.

[[ 실시예Example 1] One]

등심초rush 추출물의 제조 Preparation of extract

(주)옴니허브(http://www.omniherb.com/)에서 구입한 등심초 150g을 75% 에탄올 15,000㎖에 60℃에서 24시간 침지시킨 후 실온에서 추출액을 수득하고, 다시 75% 에탄올 15,000㎖를 가하여 2회 더 추출하여 추출액을 모았다. 상기 각 추출액을 여과한 여과물을 감압 회전농축기(Vaccum rotary evaporator; 일본 Nihon Seiko사, VR-205c)로 용매를 증발시키는 감압 농축 및 건조과정을 통하여 등심초 추출물 10.8g(수율 : 7.2%)을 수득하였다.
(150 g) purchased from Omni Hub Co., Ltd. (http://www.omniherb.com/) was immersed in 15,000 ml of 75% ethanol at 60 ° C for 24 hours, and then an extract was obtained at room temperature. Then, 15,000 ml of 75% And the extract was further extracted two more times. 10.8 g (yield: 7.2%) of R. cauliflower extract was obtained through concentration and drying at a reduced pressure of evaporating the solvent with a vacuum distillator (Vaccum rotary evaporator, VR-205c, Nihon Seiko, Japan) Respectively.

[[ 실험예Experimental Example 1] One]

DPPHDPPH 라디칼Radical 소거활성( Scavenging activity DPPHDPPH radicalradical scavengingscavenging activityactivity ) 측정) Measure

DPPH는 짙은 보라색을 띄는 비교적 안정한 자유라디칼로서 517nm에서 높은 흡광도값을 나타내며, 항산화효과가 있는 물질과 반응하면 옅은 노란색을 띄어 517nm에서의 흡광도가 감소하므로, 다양한 소재로부터 항산화물질을 검색하는데 많이 이용된다.DPPH is a relatively stable free radical with a deep purple color and exhibits a high absorbance value at 517 nm. When it reacts with a substance having antioxidative effect, it becomes pale yellow and decreases the absorbance at 517 nm. Therefore, it is widely used to search for antioxidants from various materials .

DPPH 라디칼 소거활성은 Blois(Blois MS. 1958. Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200)의 방법을 변형하여 측정하였다. The DPPH radical scavenging activity was determined by using Blois (Blois MS. 1958. Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200).

시료용액 2㎖에 0.2mM의 1,1-디페닐-2-피크릴하이드라질(1,1-diphenyl-2-picrylhydrazyl, DPPH) 1㎖를 넣어 교반하고 30분간 방치한 다음 517nm에서 흡광도를 측정하였다. 비교를 위하여 비타민 C(ascorbic acid)를 사용하여 동일하게 실험하였다.1 ml of 0.2 mM 1,1-diphenyl-2-picrylhydrazyl (DPPH) was added to 2 ml of the sample solution, and the mixture was allowed to stand for 30 minutes, and the absorbance was measured at 517 nm Respectively. For comparison, vitamin C (ascorbic acid) was used in the same experiment.

DPPH 라디칼 소거활성은 하기 수학식 1과 같이 시료용액을 첨가한 시료첨가군과 시료용액을 첨가하지 않은 무첨가군의 흡광도 감소율로 나타내었으며, 그 결과를 하기 표 1과 도 1에 나타내었다. 도 1에서 JEE는 본 발명의 등심초 추출물(Juncus effusus extract)을 나타내고 Vit. C는 비타민 C를 나타낸다.The DPPH radical scavenging activity was expressed by the absorbance decreasing rate of the sample addition group to which the sample solution was added and the no addition group to which the sample solution was not added as shown in the following Equation 1, and the results are shown in Table 1 and FIG. In Figure 1, JEE represents the jujube extract of the present invention ( Juncus effusus extract) and Vit. C represents vitamin C.

Figure pat00001
Figure pat00001

처리군Treated group 농도(㎎/㎖)Concentration (mg / ml) DPPH 라디칼 소거활성(%)DPPH radical scavenging activity (%) 등심초 추출물
Seaweed extract
0.20.2 9.96 ± 0.109.96 + 0.10
55 24.50 ± 2.3724.50 ± 2.37 비타민 CVitamin C 55 76.21 ± 6.0576.21 + - 6.05

상기 표 1의 결과에서 알 수 있듯이, 본 발명의 등심초 추출물은 비타민 C에 비해서는 낮지만 5㎎/㎖ 농도에서 상당한 DPPH 라디칼 소거활성을 나타내었다.
As can be seen from the results shown in Table 1, the watercress extract of the present invention showed a DPPH radical scavenging activity at a concentration of 5 mg / ml though it was lower than that of vitamin C.

[[ 실험예Experimental Example 2] 2]

ABTSABTS + 양이온 + Cation 라디칼Radical 소거활성( Scavenging activity ABTSABTS + + cationcation radicalradical scavengingscavenging activityactivity ) 측정) Measure

ABTS는 짙은 청록색을 띄는 자유 라디칼로서 732nm에서 높은 흡광도값을 나타내며, 항산화효과가 있는 물질과 반응하면 거의 투명한 흰색에 가까운 하늘색을 띄게 되어 732nm에서의 흡광도가 감소하므로, 다양한 소재로부터 항산화물질을 검색하는데 많이 이용된다. ABTS is a dark blue-green free radical with a high absorbance value at 732 nm. When it reacts with an antioxidant substance, the absorbance at 732 nm is reduced to near-transparent white, so that antioxidants are detected from various materials It is widely used.

ABTS 라디칼을 이용한 항산화력 측정은 ABTS+ㆍ 양이온 탈색 어세이(ABTS+ㆍ cation decolorization assay){Fellegrini N, Ka R, Yang M, Rice-Evans C. 1999. Screening of diatry carotenoids-rich fruit extracts for antioxidant activities applying 2,2'-azinobis(3-ethylenebenzeothiazoline-6-sulfonic acid) radical cation decolorization assay. Method Enzymol 299: 379-389}에 의하여 측정하였다.Antioxidant activity using ABTS radicals was measured by ABTS + cation decolorization assay (Fellegrini N, Ka R, Yang M, Rice-Evans C. 1999. Screening of diatry carotenoids-rich fruit extracts for antioxidant activities 2,2'-azinobis (3-ethylenebenzeothiazoline-6-sulfonic acid) radical cation decolorization assay. Method Enzymol 299: 379-389).

7mM 2,2-아지노-비스(3-에틸-벤티아졸린-6-술폰산){2,2 - azino - bis (3 - ethyl - benthiazoline - 6 - sulfonic acid)}과 2.4mM 포타슘 퍼설페이트(potassium persulfate)를 혼합하고 실온에서 24시간 동안 방치하여 ABTS+ㆍ를 형성시킨 후 에탄올로 희석하고 ABTS+ㆍ 100㎕에 시료용액 100㎕를 가하여 1분 동안 방치한 후 732nm에서 흡광도를 측정하였다. 비교를 위하여 비타민 C를 사용하여 동일하게 실험하였다.A solution of 7 mM 2,2-azino-bis (3-ethyl-benzothiazoline-6-sulfonic acid) {2,2-azino-bis persulfate were mixed and allowed to stand at room temperature for 24 hours to form ABTS + ㆍ. After diluting with ethanol, 100 μl of ABTS + ㆍ 100 μl of sample solution was added and left for 1 minute, and the absorbance was measured at 732 nm. Vitamin C was used for comparison for the same experiment.

ABTS 양이온 라디칼 소거활성은 하기 수학식 2와 같이 시료용액을 첨가한 시료첨가군과 시료용액을 첨가하지 않은 무첨가군의 흡광도 감소율로 나타내었으며, 그 결과를 하기 표 2와 도 2에 나타내었다. 도 2에서 JEE는 본 발명의 등심초 추출물을 나타내고 Vit. C는 비타민 C를 나타낸다.The ABTS cation radical scavenging activity was expressed by the absorbance decreasing rate of the sample addition group to which the sample solution was added and the non-addition group to which the sample solution was not added, as shown in the following Equation 2, and the results are shown in Table 2 and FIG. In FIG. 2, JEE represents the Rumex root extract of the present invention and Vit. C represents vitamin C.

Figure pat00002
Figure pat00002

처리군Treated group 농도(㎎/㎖)Concentration (mg / ml) ABTS 라디칼 소거활성(%)ABTS radical scavenging activity (%) 등심초 추출물
Seaweed extract
0.20.2 18.92 ± 0.3518.92 + 0.35
55 96.73 ± 0.8496.73 + - 0.84 비타민 CVitamin C 55 85.58 ± 1.7585.58 ± 1.75

상기 표 2의 결과에서 알 수 있듯이, 본 발명의 등심초 추출물은 0.2㎎/㎖ 농도에서도 상당한 ABTS 라디칼 소거활성을 나타냈으며, 5㎎/㎖ 농도에서는 96.73%의 매우 높은 ABTS 라디칼 소거활성을 나타내어, 동일한 농도에서 85.58%의 소거활성을 나타낸 비타민 C에 비해 ABTS 라디칼 소거활성이 훨씬 우수하였다.
As can be seen from the results of Table 2, the extract of R. codon according to the present invention exhibited a significant ABTS radical scavenging activity even at a concentration of 0.2 mg / ml, and a very high ABTS radical scavenging activity of 96.73% at a concentration of 5 mg / The ABTS radical scavenging activity was much better than that of vitamin C which showed 85.58% scavenging activity.

[[ 실험예Experimental Example 3] 3]

엘라스타제Elastase (( ElastaseElastase ) 저해활성 측정) Inhibition activity measurement

엘라스타제 저해활성은 Cannell 등(Cannell RJ, Kellam SJ, Owsianka AM, Walker JM. 1988. Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Med 54: 10-14)의 방법에 따라 측정하였다.Elastase inhibitory activity Cannell etc. (Cannell RJ, SJ Kellam, Owsianka AM, Walker JM. 1988. Results of a large scale screen of microalgae for the production of protease inhibitors. Planta Med 54: 10-14).

기질로는 N-숙시닐-(L-Ala)3-p-니트로아닐라이드 {N-succinyl-(L-Ala)3-p-nitroanilide}를 사용하였으며, 37℃에서 20분간 기질로부터 생성되는 p-니트로아닐라이드(p-nitroanilide)의 생성량을 445nm에서 측정하였다. Substrate include N- succinyl - (L-Ala) 3 -p- nitro not ride {N-succinyl- (L-Ala ) 3 -p-nitroanilide} was used, p is generated from the substrates 20 minutes at 37 ℃ The amount of p-nitroanilide produced was measured at 445 nm.

즉, 각 시험용액을 일정 농도가 되도록 조제하여 0.5㎖씩 시험관에 취하고, 50mM 트리스-HCl 버퍼(tris-HCl buffer)(pH 8.6)에 녹인 돼지 췌장 엘라스타제(porcine pancreas elastase)(2.5U/㎖)용액 0.5㎖을 가한 후 기질로 50mM 트리스-HCl 버퍼(pH 8.6)에 녹인 N-숙시닐-(L-Ala)3-p-니트로아닐라이드(0.5㎎/㎖)을 첨가하여 20분간 반응시켜 측정하였다. 비교를 위하여, 에피갈로카테킨 갈레이트(Epigallocatechin gallate, EGCG)를 사용하여 동일하게 실험하였다. That is, each test solution was prepared so as to have a constant concentration, 0.5 ml of each test solution was taken in a test tube, and porcine pancreas elastase (2.5 U / ml) dissolved in 50 mM tris-HCl buffer (pH 8.6) (L-Ala) 3 -p-nitroanilide (0.5 mg / ml) dissolved in 50 mM Tris-HCl buffer (pH 8.6) Respectively. For comparison, the same experiment was carried out using Epigallocatechin gallate (EGCG).

엘라스타제 저해활성은 하기 수학식 3과 같이 시료용액을 첨가한 시료첨가군과 시료용액을 첨가하지 않은 무첨가군의 흡광도 감소율로 나타내었으며, 그 결과를 하기 표 3과 도 3에 나타내었다. 도 3에서 JEE는 본 발명의 등심초 추출물을 나타낸다.The inhibitory activity of elastase was expressed by the absorbance decreasing rate of the sample addition group to which the sample solution was added and the non-addition group to which the sample solution was not added, as shown in the following Equation 3, and the results are shown in Table 3 and FIG. In Fig. 3, JEE represents the sirloin of the present invention.

Figure pat00003
Figure pat00003

처리군Treated group 농도(㎍/㎖)Concentration (/ / ml) 엘라스타제 저해활성(%)Elastase inhibitory activity (%) 등심초 추출물Seaweed extract 200200 104.18 ± 3.48104.18 ± 3.48 EGCGEGCG 200200 52.09 ± 3.6652.09 + - 3.66

상기 표 3의 결과에서 알 수 있듯이, 본 발명의 등심초 추출물은 200㎍/㎖ 농도에서 엘라스타제 저해활성이 104.18%로, EGCG보다 2배 높은 엘라스타제 저해활성을 나타내었다.
As can be seen from the results shown in Table 3, the extract of R. codon according to the present invention exhibited an elastase inhibitory activity of 104.18% at a concentration of 200 μg / ml, and an inhibitory activity of elastase which was two times higher than that of EGCG.

[[ 실험예Experimental Example 4] 4]

콜라게나제(collagenase ) 저해활성 측정 Collagenase (collagenase) inhibitory activity is measured

콜라게나제 저해활성은 Wunsch 등(Wunsch, E., H.G. Heindrich. 1963. Zur quantitativen bestimmung der collagenase. Hoppe Seylers. Z. Physiol. Chem. 333:149-151)의 방법에 따라 측정하였다. Collagenase inhibitory activity was measured according to the method of Wunsch et al. (Wunsch, E., H. G. Heindrich, 1963. Zur quantitativen bestimmung der collagenase.Hopepe Seylers.Z.Physiol.Chem. 333: 149-151).

즉, 반응구는 0.1M 트리스-HCl 버퍼(pH 7.5)에 4mM CaCl2를 첨가하고 4-페닐아조 벤질옥시카보닐-Pro-Leu-Gly-Pro-D-Arg(4-phenylazo benzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg)(0.3㎎/㎖)를 녹인 기질액 0.25㎖와 시료용액 0.1㎖를 혼합한 혼합액에 콜라게나제(0.5㎎/㎖) 0.15㎖를 첨가하여 실온에서 20분간 방치한 후 6% 시트르산(citric acid) 0.5㎖을 넣어 반응을 정지시키고 에틸아세테이트(ethyl acetate) 3㎖를 첨가하여 320nm에서 흡광도를 측정하였다. 비교를 위하여, EGCG를 사용하여 동일하게 실험하였다. That is, the reaction mixture was prepared by adding 4 mM CaCl 2 to 0.1 M Tris-HCl buffer (pH 7.5), adding 4-phenylazo benzyloxycarbonyl-Pro-Leu 0.15 ml of collagenase (0.5 mg / ml) was added to a mixture of 0.25 ml of the substrate solution and 0.1 ml of the sample solution, and the mixture was allowed to stand at room temperature for 20 minutes After adding 0.5 ml of 6% citric acid, the reaction was stopped and 3 ml of ethyl acetate was added to measure the absorbance at 320 nm. For comparison, the same experiment was carried out using EGCG.

콜라게나제 저해활성은 하기 수학식 4와 같이 시료용액을 첨가한 시료첨가군과 시료용액을 첨가하지 않은 무첨가군의 흡광도 감소율로 나타내었으며, 그 결과를 하기 표 4와 도 4에 나타내었다. 도 4에서 JEE는 본 발명의 등심초 추출물을 나타낸다.The collagenase inhibitory activity was expressed by the absorbance decreasing rate of the sample addition group to which the sample solution was added and the non-addition group to which the sample solution was not added, as shown in the following Equation 4, and the results are shown in Table 4 and FIG. In FIG. 4, JEE represents the sirloin of the present invention.

Figure pat00004
Figure pat00004

처리군Treated group 농도(㎍/㎖)Concentration (/ / ml) 콜라게나제 저해활성(%)Collagenase inhibitory activity (%) 등심초 추출물Seaweed extract 200200 70.38 ± 0.4670.38 + - 0.46 EGCGEGCG 200200 41.89 ± 4.4941.89 + - 4.49

상기 표 4의 결과에서 알 수 있듯이, 본 발명의 등심초 추출물은 200㎍/㎖ 농도에서 콜라게나제 저해활성이 70.38%로, EGCG의 거의 2배에 해당하는 높은 저해활성을 나타내었다.
As can be seen from the results of Table 4, the extract of R. codon according to the present invention showed a high inhibitory activity of collagenase inhibitory activity of 70.38% at a concentration of 200 μg / ml, which is almost twice that of EGCG.

Claims (3)

등심초 추출물을 유효성분으로 포함하는 피부탄력 및 주름 개선용 화장료 조성물.A cosmetic composition for improving skin elasticity and wrinkles, comprising an extract of rosemary extract as an active ingredient. 제1항에 있어서,
상기 등심초 추출물은 물, C1 내지 C4의 저급 알콜 및 이들의 혼합용매로부터 선택된 용매로 추출된 것임을 특징으로 하는 조성물.
The method according to claim 1,
Characterized in that the rumen extract is extracted with a solvent selected from water, C 1 to C 4 lower alcohols and mixed solvents thereof.
제1항 또는 제2항에 있어서,
상기 조성물은 상기 등심초 추출물을 화장료 조성물 총 중량에 대하여 0.1~50중량% 포함하는 것을 특징으로 하는 조성물.
3. The method according to claim 1 or 2,
Wherein the composition comprises from 0.1 to 50% by weight, based on the total weight of the cosmetic composition.
KR1020140094816A 2014-07-25 2014-07-25 Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle Ceased KR20160013435A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140094816A KR20160013435A (en) 2014-07-25 2014-07-25 Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140094816A KR20160013435A (en) 2014-07-25 2014-07-25 Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle

Publications (1)

Publication Number Publication Date
KR20160013435A true KR20160013435A (en) 2016-02-04

Family

ID=55356152

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140094816A Ceased KR20160013435A (en) 2014-07-25 2014-07-25 Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle

Country Status (1)

Country Link
KR (1) KR20160013435A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230084996A (en) 2021-12-06 2023-06-13 한국한의약진흥원 Antithrombotic composition comprising rush extract
CN117045559A (en) * 2023-09-11 2023-11-14 云南贝泰妮生物科技集团股份有限公司 Preparation method of erigeron breviscapus extract, product and application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230084996A (en) 2021-12-06 2023-06-13 한국한의약진흥원 Antithrombotic composition comprising rush extract
CN117045559A (en) * 2023-09-11 2023-11-14 云南贝泰妮生物科技集团股份有限公司 Preparation method of erigeron breviscapus extract, product and application thereof

Similar Documents

Publication Publication Date Title
KR102047234B1 (en) Composition for Improving Skin Conditions with Improved Skin Whitening, Antioxidant, Moisturizing, Anti-wrinkling, and Regeneration Property Comprising Callus Extract of Hibiscus Syriacus
KR20180069756A (en) Cosmetic Composition for comprising longanae arillus extracts
JP6437342B2 (en) A skin external preparation or an internal preparation containing an extract of echinacea cultivated by irradiating light having a specific wavelength range.
KR102425559B1 (en) Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom
KR20170055172A (en) Cosmetic Composition Comprising Extracts of Centipeda minima
KR101872357B1 (en) Cosmetic composition for enhancing skin elasticity containing extract of rhamnus yoshinoi
KR20160013435A (en) Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle
KR20140097865A (en) Cosmetic composition comprising Laver extract for anti-inflammation
KR20190116620A (en) A composition comprising loliolide for improving skin wrinkle
KR102226179B1 (en) Cosmetic Compositions for Anti-aging Comprising Extracts of Plants
KR20180027213A (en) Composition for skin improvement containing Salvianolic acid C
KR101883307B1 (en) Cosmetic composition for improving skin wrinkle comprising extracts of hibiscus hamabo leaf as active ingredient
KR101922089B1 (en) Cosmetic Composition for comprising longanae arillus extracts
KR101776692B1 (en) Composiitn for skin whitening comprising extract of Osmanthus heterophylla
KR20180068904A (en) Cosmetic composition for improving skin wrinkle containing extract of rhamnus yoshinoi
KR101317433B1 (en) The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage
KR20180090123A (en) Composition for skin improvement containing liquidambaric lactone
KR20180045626A (en) Composition for skin improvement containing valechlorine
KR100467501B1 (en) A cosmetic composite
KR102430512B1 (en) Reelin/vegf-c production/activation promoter and skin external composition using the same
KR102461962B1 (en) Cosmetic composition for wrinkles prevention or improvement with seaberry extraction
KR102152932B1 (en) Composition for improving skin conditions comprising catechin glycoside and method for improving skin conditions using the same
KR100678865B1 (en) Cosmetic composition for skin whitening containing upper limb extract and carnitine as active ingredients
KR102053731B1 (en) A cosmetic composition for skin tenperature control comprising spirulina extract and methods
KR102134150B1 (en) A composition comprising extract of Prasiola japonica for improving skin wrinkle caused by photoaging

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20140725

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20181016

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190725

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20140725

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201124

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20210414

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201124

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I